@sigtrans-sttt.bsky.socialWho benefits most from consolidation #Immunotherapy in limited-stage #SCLC?
Integrating #ctDNA status with tumor shrinkage identifies high-risk patients deriving survival benefit, while sustained ctDNA negativity predicts favorable outcomes.
@cancergrace.bsky.social
@lungcancereurope.bsky.social200+ people have registered for today’s #SCLC webinar. There’s still time to join us.
We’ll hear from people living with SCLC and others affected by it, alongside clinicians, about diagnosis, treatment and support.
15:00 CEST / 14:00 BST